Drug Profile
Revefenacin - Viatris/Theravance Biopharma
Alternative Names: 1160724; GSK 1160724; Revefenacin inhalation solution; TD 4208; TD-4028; YUPELRILatest Information Update: 15 Nov 2023
Price :
$50
*
At a glance
- Originator Theravance
- Developer Theravance Biopharma; Viatris Inc
- Class Biphenyl compounds; Bronchodilators; Carbamates; Piperidines; Small molecules
- Mechanism of Action Muscarinic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
Most Recent Events
- 13 Nov 2023 Viatris intends to submit regulatory filing for Chronic obstructive pulmonary disease in China in mid-2024
- 13 Nov 2023 Efficacy data from a phase III trial in Chronic obstructive pulmonary disease released by Viatris and Theravance Biopharma
- 26 Jul 2023 Mylan Pharmaceuticals completes a phase III trials in Chronic obstructive pulmonary disease in China (Inhalation) (NCT05046795)